Meditera

The page describes cassette mechanisms and volumetric infusion pumps for clinical excellence in IV applications.

The company offers infusion systems, chemotherapy solutions, cytotoxic oncology drug preparation sets, and drug preparation room installation services.

Meditera Tibbi Malzeme Sanayi ve Ticaret reports third-quarter 2026 sales of **TRY 797.7 million** (down from **TRY 840.98 million** year-over-year) and net income of **TRY 9.14 million** (down from **TRY 33.62 million**). For the nine-month period, sales total **TRY 2,233.43 million** (down from **TRY 2,592.46 million**), with a net loss of **TRY 73.41 million** (improved from a **TRY 97.14 million** loss).

Nov 2026MarketScreenerNews article

Meditera Tibbi Malzeme Sanayi ve Ticaret reports second-quarter 2026 sales of **TRY 668.47 million**, down from **TRY 818.33 million** in the same period last year. The company’s net loss narrows to **TRY 19.37 million** (vs. **TRY 25.84 million** year-over-year), with basic and diluted loss per share at **TRY 0.16** each. Results cover the six-month period ending June 30, 2026.

Aug 2026MarketScreenerNews article

Meditera Tibbi Malzeme Sanayi ve Ticaret reports first-quarter 2026 sales of **TRY 646.21 million**, down from **TRY 785.67 million** in the same period last year. The company’s net loss narrows to **TRY 54.97 million**, improving from a **TRY 91.6 million** loss year-over-year. Results reflect continued financial challenges amid declining revenue.

May 2026MarketScreenerNews article

Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Şirketi reports **TRY 2.87 billion in sales** for 2025, up from TRY 2.74 billion in 2024. The company records a **net loss of TRY 9.27 million**, reversing a prior net income of TRY 96.11 million. Financial performance reflects a shift from profitability to a modest loss despite revenue growth.

Mar 2026MarketScreenerNews article